Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation—A systematic review and meta-analysis

Double filtration plasmapheresis: A new road for donor‐specific antibody desensitization in allogeneic stem cell transplantation

“…For mismatched donor transplantation, especially haploidentical transplantation, DSAs have been recognized as an important barrier against successful engraftment of donor cells. The relationship of DSAs and primary graft failure (PGF) has been clarified and DSAs not only significantly increase the risk of PGF, but also could result in a higher incidence of primary poor graft function 1–3 …”

“…The relationship of DSAs and primary graft failure (PGF) has been clarified and DSAs not only significantly increase the risk of PGF, but also could result in a higher incidence of primary poor graft function. [1][2][3] To reduce the risk of PGF, several desensitization methods have been used to decrease DSA levels or inhibit its production that would permit successful donor stem cell engraftment (Table 1). These desensitization methods are mostly based on experiences in solid organ transplantation.…”

Case report: Curing a rare, unstable hemoglobin variant Hb Bristol-Alesha using haploidentical hematopoietic stem cell transplantation

“…DSAs are a major cause of primary GF, including graft rejection (GR) and poor graft function (PGF) in patients receiving haplo-HSCT (42,43). The rejection rate is much higher in the DSA-positive group than in the DSA-negative group, and DSA-positive patients have worse OS and inferior progression-free survival (44,45). Therefore, anti-HLA antibodies should be evaluated in all haplo-HSCT recipients, especially in those receiving multiple transfusions (46).…”

Double filtration plasmapheresis combined with rituximab for donor‐specific antibody desensitization in haploidentical haematopoietic stem cell transplantation

“…Although Haplo‐HSCT has made rapid progress in recent years, there are still some key problems to solve, one of which is the existence of donor‐specific anti‐HLA antibodies (DSAs) 4 . Lots of studies have proved that DSA may be positively associated with the occurrence of engraftment failure and poor graft function (PGF), and then in turn increases the incidence of non‐relapse mortality (NRM) and negatively affects outcomes of patients 5–7 …”

“…4 Lots of studies have proved that DSA may be positively associated with the occurrence of engraftment failure and poor graft function (PGF), and then in turn increases the incidence of non-relapse mortality (NRM) and negatively affects outcomes of patients. [5][6][7] While selecting a donor without corresponding HLA to recipient's anti-HLA antibodies is an ideal option, it might…”